Charles River Laboratories

Charles River Laboratories is a leading global provider of essential products and services to advance the research and development of medical therapies. Founded in 1947, the company plays a critical role in the pharmaceutical industry and biotechnology sectors by supplying research models and offering contract research services. Its work supports clients from early-stage discovery through regulatory approval, operating under stringent quality standards to ensure data integrity and reproducibility.

History

The company was established in 1947 by veterinarian Henry L. Foster in a converted Boston warehouse, initially breeding and selling laboratory rodents for research. Its early growth was propelled by the post-war expansion of the National Institutes of Health and the increasing demand for standardized animal models in biomedical research. A significant milestone was the acquisition by Bausch & Lomb in 1984, followed by a leveraged buyout in 1999 that returned it to independent status before its initial public offering on the New York Stock Exchange in 2000. Strategic acquisitions, such as Wilmington-based Inveresk Research Group in 2004, WIL Research in 2016, and Citoxlab in 2019, have dramatically expanded its service capabilities and global footprint across North America, Europe, and Asia.

Business segments

The company operates through three primary business segments. The Research Models and Services segment provides genetically engineered mice and rats, along with associated biological products and diagnostic services, which are fundamental for genetics and oncology studies. The Discovery and Safety Assessment segment offers a comprehensive suite of contract research services, including toxicology, pharmacology, and chemistry, manufacturing, and controls (CMC) support, crucial for Investigational New Drug (IND) applications. The Manufacturing Support segment focuses on microbial and viral testing solutions, utilizing technologies like endotoxin detection and polymerase chain reaction (PCR) to ensure the safety of biologics and medical devices for clients like Johnson & Johnson and Pfizer.

Products and services

Its core offerings include the production and characterization of specific pathogen-free and immunodeficient rodent models, which are vital for studies in immunology and infectious disease research. The company's safety assessment services encompass regulatory toxicology studies required by agencies like the Food and Drug Administration and the European Medicines Agency, as well as developmental and reproductive toxicology testing. Advanced service platforms include genomic and biomarker analysis, vaccine development support, and Good Laboratory Practice (GLP)-compliant bioanalysis. It also provides essential in vitro testing products, such as the Limulus Amebocyte Lysate (LAL) test for bacterial endotoxin detection.

Regulatory and ethical considerations

As a major user of animals in research, the company's operations are governed by stringent regulations, including the Animal Welfare Act in the United States and Directive 2010/63/EU in the European Union. It maintains accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and adheres to the principles of the 3Rs (Replacement, Reduction, Refinement). The company has faced scrutiny from animal rights organizations such as People for the Ethical Treatment of Animals (PETA) and has been involved in regulatory actions by the United States Department of Agriculture. It maintains an institutional Animal Care and Use Committee (IACUC) to oversee welfare standards.

Financial performance

The company has demonstrated consistent revenue growth, reporting US$4.13 billion in total revenue for the 2023 fiscal year, a significant increase from US$3.88 billion in 2022. This performance is driven by strong demand across its safety assessment and manufacturing support segments, particularly from the biopharmaceutical sector. It is publicly traded on the New York Stock Exchange under the ticker symbol CRL and is a constituent of the S&P 500 index. Major financial events include strategic investments in new facilities in Springfield and Reno, and navigating macroeconomic challenges like inflation and supply chain constraints affecting global operations.

Category:Companies based in Massachusetts Category:Pharmaceutical companies of the United States Category:Companies listed on the New York Stock Exchange